Patents by Inventor Marina Kapfer
Marina Kapfer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9024003Abstract: The present invention notably relates to novel recombinant telomerase reverse transcriptases, nucleic acid molecules coding them, cells comprising said nucleic acid molecule and use of these cells for the production of substance of interest.Type: GrantFiled: January 5, 2007Date of Patent: May 5, 2015Assignee: Transgene S.A.Inventors: Philippe Erbs, Jean-Marc Balloul, Marina Kapfer, Nathalie Silvestre
-
Patent number: 8809056Abstract: This invention relates to immortalized avian cells, and to the use of these cells for the production of viruses. The cells according to the invention are particularly useful for the production of recombinant viral vectors which can be used for the preparation of therapeutic and/or prophylactic compositions for the treatment of animals and more particularly humans.Type: GrantFiled: December 21, 2012Date of Patent: August 19, 2014Assignee: Transgene S.A.Inventors: Phillippe Erbs, Marina Kapfer, Nathalie Silvestre
-
Patent number: 8778675Abstract: The present invention relates to specific immortalized avian cell lines expressing telomerase reverse transcriptase (TERT), and exhibiting distinct biologics production patterns. More particularly, the present invention relates to immortalized avian cell line capable of either amplifying Flaviviridae but not capable of amplifying Vaccinia virus strain Copenhagen (VV-COP) nor Modified Vaccinia virus Ankara (MVA), or capable of amplifying both Flaviviridae and Poxviridae. The invention further relates to the use of said immortalized avian cell lines and related methods for producing biologics, including viruses and proteins.Type: GrantFiled: February 25, 2013Date of Patent: July 15, 2014Assignee: Transgene S.A.Inventors: Jean-Marc Balloul, Marina Kapfer, Thierry Menguy
-
Publication number: 20130244246Abstract: This invention relates to immortalized avian cells, and to the use of these cells for the production of viruses. The cells according to the invention are particularly useful for the production of recombinant viral vectors which can be used for the preparation of therapeutic and/or prophylactic compositions for the treatment of animals and more particularly humans.Type: ApplicationFiled: December 21, 2012Publication date: September 19, 2013Applicant: TRANSGENE S.A.`Inventors: Philippe Erbs, Marina Kapfer, Nathalie Silvestre
-
Publication number: 20130236929Abstract: The present invention relates to specific immortalized avian cell lines expressing telomerase reverse transcriptase (TERT), and exhibiting distinct biologics production patterns. More particularly, the present invention relates to immortalized avian cell line capable of either amplifying Flaviviridae but not capable of amplifying Vaccinia virus strain Copenhagen (VV-COP) nor Modified Vaccinia virus Ankara (MVA), or capable of amplifying both Flaviviridae and Poxviridae. The invention further relates to the use of said immortalized avian cell lines and related methods for producing biologics, including viruses and proteins.Type: ApplicationFiled: February 25, 2013Publication date: September 12, 2013Applicant: TRANSGENE S.A.Inventors: Jean-Marc Balloul, Marina Kapfer, Thierry Menguy
-
Patent number: 8513018Abstract: This invention relates to immortalized avian cells, including those deposited under accession numbers 09070701, 09070702, and 09070703 at the ECACC, and to the use of these cells for the production of viruses. The cells according to the invention are particularly useful for the production of recombinant viral vectors which can be used for the preparation of therapeutic and/or prophylactic compositions for the treatment of animals and more particularly humans.Type: GrantFiled: May 29, 2012Date of Patent: August 20, 2013Assignee: Transgene S.A.Inventors: Philippe Erbs, Marina Kapfer, Nathalie Silvestre
-
Patent number: 8445270Abstract: The present invention relates to specific immortalized avian cell lines expressing telomerase reverse transcriptase (TERT), and exhibiting distinct biologics production patterns. More particularly, the present invention relates to immortalized avian cell line capable of either amplifying Flaviviridae but not capable of amplifying Vaccinia virus strain Copenhagen (VV-COP) nor Modified Vaccinia virus Ankara (MVA), or capable of amplifying both Flaviviridae and Poxviridae. The invention further relates to the use of said immortalized avian cell lines and related methods for producing biologics, including viruses and proteins.Type: GrantFiled: May 11, 2010Date of Patent: May 21, 2013Assignee: Transgene S.A.Inventors: Jean-Marc Balloul, Marina Kapfer, Thierry Menguy
-
Publication number: 20130095557Abstract: This invention relates to immortalized avian cells, including those deposited under accession numbers 09070701, 09070702, and 09070703 at the ECACC, and to the use of these cells for the production of viruses. The cells according to the invention are particularly useful for the production of recombinant viral vectors which can be used for the preparation of therapeutic and/or prophylactic compositions for the treatment of animals and more particularly humans.Type: ApplicationFiled: June 29, 2011Publication date: April 18, 2013Applicant: TRANSGENE S.A.Inventors: Philippe Erbs, Marina Kapfer, Nathalie Silvestre
-
Patent number: 8361788Abstract: Immortalized avian cell lines containing E1A nucleic acid sequences are useful for the production of viruses and are particularly useful for the production of recombinant viral vectors which can be employed for the preparation of therapeutic and/or prophylactic compositions for the treatment of animals and more particularly humans.Type: GrantFiled: July 2, 2008Date of Patent: January 29, 2013Assignee: Transgene S.A.Inventors: Philippe Erbs, Marina Kapfer, Nathalie Silvestre
-
Patent number: 8357531Abstract: This invention relates to immortalized avian cells, including those deposited under accession numbers 09070701, 09070702, and 09070703 at the ECACC, and to the use of these cells for the production of viruses. The cells according to the invention are particularly useful for the production of recombinant viral vectors which can be used for the preparation of therapeutic and/or prophylactic compositions for the treatment of animals and more particularly humans.Type: GrantFiled: July 2, 2010Date of Patent: January 22, 2013Assignee: Transgene S.A.Inventors: Philippe Erbs, Marina Kapfer, Nathalie Silvestre
-
Publication number: 20120238000Abstract: This invention relates to immortalized avian cells, including those deposited under accession numbers 09070701, 09070702, and 09070703 at the ECACC, and to the use of these cells for the production of viruses. The cells according to the invention are particularly useful for the production of recombinant viral vectors which can be used for the preparation of therapeutic and/or prophylactic compositions for the treatment of animals and more particularly humans.Type: ApplicationFiled: May 29, 2012Publication date: September 20, 2012Applicant: Transgene S.A.Inventors: Philippe Erbs, Marina Kapfer, Nathalie Silvestre
-
Publication number: 20120122155Abstract: The present invention relates to specific immortalized avian cell lines expressing telomerase reverse transcriptase (TERT), and exhibiting distinct biologics production patterns. More particularly, the present invention relates to immortalized avian cell line capable of either amplifying Flaviviridae but not capable of amplifying Vaccinia virus strain Copenhagen (W—COP) nor Modified Vaccinia virus Ankara (MVA), or capable of amplifying both Flaviviridae and Poxviridae. The invention further relates to the use of said immortalized avian cell lines and related methods for producing biologics, including viruses and proteins.Type: ApplicationFiled: May 11, 2010Publication date: May 17, 2012Applicant: TRANSGENE S.A.Inventors: Jean-Marc BALLOUL, Marina KAPFER, Thierry MENGUY
-
Publication number: 20110212488Abstract: The present invention relates to specific immortalized avian cell lines expressing telomerase reverse transcriptase (TERT), and exhibiting distinct biologics production patterns. More particularly, the present invention relates to immortalized avian cell line capable of either amplifying Flaviviridae but not capable of amplifying Vaccinia virus strain Copenhagen (W—COP) nor Modified Vaccinia virus Ankara (MVA), or capable of amplifying both Flaviviridae and Poxyiridae. The invention further relates to the use of said immortalized avian cell lines and related methods for producing biologics, including viruses and proteins.Type: ApplicationFiled: May 11, 2010Publication date: September 1, 2011Applicant: TRANSGENE S.A.Inventors: Jean-Marc BALLOUL, Marina KAPFER, Thierry MENGUY
-
Publication number: 20110008872Abstract: This invention relates to immortalized avian cells, including those deposited under accession numbers 09070701, 09070702, and 09070703 at the ECACC, and to the use of these cells for the production of viruses. The cells according to the invention are particularly useful for the production of recombinant viral vectors which can be used for the preparation of therapeutic and/or prophylactic compositions for the treatment of animals and more particularly humans.Type: ApplicationFiled: July 2, 2010Publication date: January 13, 2011Applicant: Transgene S.A.Inventors: Philippe ERBS, Marina Kapfer, Nathalie Silvestre
-
Publication number: 20100197010Abstract: Immortalized avian cell lines containing E1A nucleic acid sequences are useful for the production of viruses and are particularly useful for the production of recombinant viral vectors which can be employed for the preparation of therapeutic and/or prophylactic compositions for the treatment of animals and more particularly humans.Type: ApplicationFiled: July 2, 2008Publication date: August 5, 2010Inventors: Philippe Erbs, Marina Kapfer, Nathalie Silvestre
-
Publication number: 20100173378Abstract: The present invention notably relates to novel recombinant telomerase reverse transcriptases, nucleic acid molecules coding them, cells comprising said nucleic acid molecule and use of these cells for the production of substance of interest.Type: ApplicationFiled: January 5, 2007Publication date: July 8, 2010Applicant: Transgene S.A.Inventors: Philippe Erbs, Jean-Marc Balloul, Marina Kapfer, Nathalie Silvestre